Insignificant effects of loss of heterozygosity in HLA in the efficacy of immune checkpoint blockade treatment.

Although the loss of heterozygosity in HLA was generally expected to be an inhibitory factor in the immune treatment response by causing T cell immune evasion, our analysis demonstrates no explicit relationships.